Table 2.

Lower thoracic aortic flow and total systemic vascular resistance index measurements before (baseline) and 5 min after LMBO

			QLTAF, µl⋅min−1⋅g−1		TSVRI, mmHg⋅min⋅g⋅ml−1
Genotype	Treatment	n	Baseline	LMBO	Baseline	LMBO
Ndufs4+/+	Saline	5	197 ± 13	197 ± 12	153 ± 11	161 ± 16
Ndufs4−/−	Saline	5	233 ± 11	230 ± 8	154 ± 12	143 ± 7
Ndufs4+/+	DMSO 100% (0.5 ml/kg)	5	224 ± 7	228 ± 8	142 ± 10	154 ± 22
Ndufs4+/+	Piericidin A (0.5 mg/kg)	5	212 ± 10	202 ± 11	140 ± 16	151 ± 24
Ndufs4+/+	After 3 wk at ${\text{F}\mathrm{i}}_{{\text{O}}_{\text{2}}}$ 0.11	5	187 ± 20	185 ± 22	167 ± 26	168 ± 17
Ndufs4−/−	After 3 wk at ${\text{F}\mathrm{i}}_{{\text{O}}_{\text{2}}}$ 0.11	5	218 ± 20	205 ± 18	147 ± 14	148 ± 8

Values are means ± SE. The effect of LMBO on each parameter was analyzed in each group by ANOVA with a post hoc correction for multiple comparisons. ${\text{F}\mathrm{i}}_{{\text{O}}_{\text{2}}}$, fraction of inspired oxygen; LMBO, left mainstem bronchial occlusion; Q_LTAF, lower thoracic aortic blood flow; TSVRI, total systemic vascular resistance index.